• Route 92 Medical raised an additional $50 million, bringing its Series F funding to $82 million, with Novo Holdings joining as a new investor.
  • The funds will accelerate the global expansion of its neurovascular products for stroke treatment and seek regulatory approvals.
  • Novo Holdings' Noel Jee joins the board, bringing life sciences expertise to aid Route 92's growth and commercialization efforts.

Route 92 Medical, Inc., a private company focused on advancing neurovascular intervention technology, has announced a $50 million extension to its oversubscribed Series F funding, bringing the total to $82 million.

Novo Holdings joined existing investors, including U.S. Venture Partners, Norwest Venture Partners, InnovaHealth Partners, and The Vertical Group, in backing this round. As part of the investment, Noel Jee, Partner of Growth Investments at Novo Holdings US, has joined the Route 92 Board of Directors. Jee brings over a decade of experience in life sciences investment and consulting.

“Our company is focused on improving outcomes for patients suffering from acute ischemic stroke, and we are continuing to build our industry-leading commercial and support teams to bring our Tenzing, FreeClimb, HiPoint, and Monopoint products to the market,” said Tony Chou, Chief Executive Officer and Founder at Route 92 Medical.
“Novo Holdings’ investment validates our clinical and commercial performance and will help us better serve patients and our interventionalist customers.”

The funds will be used to accelerate the global rollout of the company’s neurovascular products and seek regulatory approvals in new markets. Route 92 Medical has developed a streamlined approach to neurovascular intervention, featuring a range of reperfusion and access systems built around its patented Tenzing delivery catheter.

These systems are designed to improve the efficiency of endovascular thrombectomy, helping doctors restore blood flow quickly in patients suffering from acute ischemic stroke, the most common form of stroke.

Edited by Harshajit Sarmah

ALSO READ:

Mental Health Platform LISSUN Raises $2.5M in its Pre-Series A Funding Led by RPSG Capital Ventures
Since its inception, LISSUN has been at the forefront of transforming mental healthcare with a holistic approach centered on Awareness, Acceptance, Anonymity, Access, Affordability, and Assurance.
NewzchainHarshajit Sarmah